Cyclophosphamide/Fludarabine/Rituximab and Hyaluronidase Regimen

Preferred Label : Cyclophosphamide/Fludarabine/Rituximab and Hyaluronidase Regimen;

NCIt synonyms : Rituxan Hycela-FC; Cyclophosphamide/Fludarabine/ Rituxan Hycela; Cyclophosphamide/Fludarabine/Rituximab and Hyaluronidase; FCR (Rituxan Hycela); Cyclophosphamide-Fludarabine-Rituximab and Hyaluronidase; Cyclophosphamide/Fludarabine/Rituximab and Hyaluronidase Human; Cyclophosphamide-Fludarabine-Rituximab and Human Hyaluronidase; Cyclophosphamide-Fludarabine-Rituxan Hycela Regimen; FCR (Rituximab and Hyaluronidase); FC- Rituxan Hycela;

NCIt definition : A regimen consisting of fludarabine, cyclophosphamide and a fixed combination of rituximab and human hyaluronidase that can be used for the treatment of chronic lymphocytic leukemia (CLL).;

NCI Metathesaurus CUI : CL1920745;

Codes from synonyms : 47670;

Details

Origin ID

C201883;

UMLS CUI

C5908228;

Semantic type(s)
- Therapeutic or Preventive Procedure [UMLS semantic type]
chemotherapy_regimen_has_component
- Cyclophosphamide [NCIt concept]
- Fludarabine [NCIt concept]
- Rituximab and Hyaluronidase Human [NCIt concept]
concept_is_in_subset
- HemOnc Regimen Terminology [NCIt concept]
- Multi-agent Therapeutic Regimens [NCIt concept]
- Pharmacotherapy Regimens [NCIt concept]
regimen_has_accepted_use_for_disease
- Chronic Lymphocytic Leukemia [NCIt concept]

Keyword's position in hierarchy(ies) :

You can consult :

recommendations
documents concerning education
documents for patients